Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland....
+See More2020-05-07 08:26:00 Thursday ET

Disruptive innovators often apply their 5 major pragmatic skills in new blue-ocean niche discovery and market share dominance. Jeff Dyer, Hal Gregersen,
2019-09-09 20:38:00 Monday ET

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch
2019-09-17 08:33:00 Tuesday ET

Global stock market investors foresee the harbinger of a major economic downturn. Many stock market investors become anxious due to negative term spreads an
2019-02-28 12:39:00 Thursday ET

New York Fed CEO John Williams sees no need to raise the interest rate unless economic growth or inflation rises to a high gear. After raising the interest
2017-06-15 07:32:00 Thursday ET

President Donald Trump has discussed with the CEOs of large multinational corporations such as Apple, Microsoft, Google, and Amazon. This discussion include
2019-04-03 11:35:00 Wednesday ET

A Florida fintech group Fidelity Information Services initiates the largest $43 billion acquisition of the e-commerce payments processor Worldpay. Fidelity